A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly HLA-sensitized Transplant Patients.
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Liver transplant rejection; Renal transplant rejection
- Focus Therapeutic Use
- 12 Feb 2019 Planned number of patients changed from 20 to 30.
- 15 Oct 2013 New trial record